Futura Medical is based in Guildford, United Kingdom (“UK”) and is listed on the AIM market of the London Stock Exchange. We are an agile, driven and committed team with extensive experience in the research, development and commercialisation of consumer health products in all of the key global consumer healthcare markets.
Our lead product is Eroxon®a clinically proven breakthrough treatment for erectile dysfunction
Futura has two new projects in its development pipeline, Eroxon® Intense for the treatment of erectile dysfunction and WSD4000 for the treatment of symptoms of impaired sexual response and function in women
Futura Medical specialises in the development and global commercialisation of innovative consumer-focused sexual health products. Our lead projects are Eroxon® (available commercially) and Eroxon® Intense and WSD4000 (both in-development). Our core strengths lie in our expertise in research and development, regulatory and business development in the sexual health market.
WEBCASTS
Videos and webcasts
Shareholder centre
This section contains the latest RNS, news and videos.
Financial calendar
01 September 2026
29 June 2026
©2026 Futura Medical
